RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Calithera Biosciences Stock

Calithera Biosciences P/E 2024

Calithera Biosciences P/E

-0.01

Ticker

CALA

ISIN

US13089P1012

WKN

A12AQH

As of Nov 22, 2024, Calithera Biosciences's P/E ratio was -0.01, a -95.83% change from the -0.24 P/E ratio recorded in the previous year.

The Calithera Biosciences P/E history

Calithera Biosciences Aktienanalyse

What does Calithera Biosciences do?

Calithera Biosciences Inc is a biopharmaceutical company specializing in the development of novel drugs for the treatment of cancer and other diseases. The company was founded in 2010 in South San Francisco, California, and has since made significant progress. History Calithera was founded by a group of successful leaders in the biotech industry who brought their extensive experience and knowledge into the development of innovative therapies. The company began its operations with the aim of finding novel molecular targets and compounds that have the potential to specifically attack cancer cells. The first product developed by the company was CB-839, an inhibitor of the enzyme glutaminase. The drug has the potential to inhibit the growth of cancer cells by disrupting the metabolic process in the cancer cells. CB-839 is currently undergoing clinical trials for the treatment of various types of cancer. Business Model Calithera Biosciences aims to address unmet medical needs by developing innovative and novel approaches to cancer and other diseases. The company takes a systematic approach and utilizes advanced technologies and research findings to develop new therapies. It works closely with leading research institutions and pharmaceutical companies to identify and develop new targets and compounds. Calithera Biosciences follows a pipeline strategy, having multiple compounds in various stages of clinical development. The company focuses on developing drugs that have high efficacy and targeted effects on cancer cells. Various Divisions Calithera Biosciences focuses on the development of drugs for the treatment of cancer and other diseases. The company has focused on researching compounds that target various factors responsible for cancer growth. The main divisions of the company are: - Metabolism: Calithera Biosciences has focused on developing drugs that inhibit the metabolism of cancer cells. CB-839, the first drug developed by the company, is an inhibitor of the enzyme glutaminase, which is important for the metabolism of cancer cells. - Immunotherapy: Calithera Biosciences has also focused on developing drugs that stimulate the immune system to fight cancer cells. The company is working on the development of drugs targeting myeloid-derived suppressor cells, a type of immune cells present in tumors. Products Calithera Biosciences has several products in development that aim to specifically attack and inhibit cancer cells. The company's key products include: - CB-839: CB-839 is an inhibitor of the enzyme glutaminase, which is important for the metabolism of cancer cells. The drug is currently undergoing clinical trials for the treatment of various types of cancer. - CB-1158: CB-1158 is an inhibitor of arginase, an enzyme important for the metabolism of immune cells. The drug has the potential to inhibit the growth of cancer cells by strengthening the immune system. CB-1158 is currently undergoing clinical trials for the treatment of various types of cancer. Conclusion Calithera Biosciences is an innovative biopharmaceutical company with a strong focus on the development of novel drugs for the treatment of cancer and other diseases. The company has focused on researching compounds that have targeted effects on cancer cells and stimulate the immune system to fight cancer cells. With a variety of compounds in different stages of clinical development, it is well positioned to bring groundbreaking therapies to the market. Calithera Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Calithera Biosciences's P/E Ratio

The Price to Earnings (P/E) Ratio of Calithera Biosciences is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Calithera Biosciences's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Calithera Biosciences is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Calithera Biosciences’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Calithera Biosciences stock

What is the price-to-earnings ratio of Calithera Biosciences?

The price-earnings ratio of Calithera Biosciences is currently -0.01.

How has the price-earnings ratio of Calithera Biosciences changed compared to last year?

The price-to-earnings ratio of Calithera Biosciences has increased by -95.83% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Calithera Biosciences high compared to other companies?

Yes, the price-to-earnings ratio of Calithera Biosciences is high compared to other companies.

How does an increase in the price-earnings ratio of Calithera Biosciences affect the company?

An increase in the price-earnings ratio of Calithera Biosciences would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Calithera Biosciences affect the company?

A decrease in the price-earnings ratio of Calithera Biosciences would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Calithera Biosciences?

Some factors that influence the price-earnings ratio of Calithera Biosciences are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Calithera Biosciences pay?

Over the past 12 months, Calithera Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Calithera Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Calithera Biosciences?

The current dividend yield of Calithera Biosciences is .

When does Calithera Biosciences pay dividends?

Calithera Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Calithera Biosciences?

Calithera Biosciences paid dividends every year for the past 0 years.

What is the dividend of Calithera Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Calithera Biosciences located?

Calithera Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Calithera Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Calithera Biosciences from 11/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/22/2024.

When did Calithera Biosciences pay the last dividend?

The last dividend was paid out on 11/22/2024.

What was the dividend of Calithera Biosciences in the year 2023?

In the year 2023, Calithera Biosciences distributed 0 USD as dividends.

In which currency does Calithera Biosciences pay out the dividend?

The dividends of Calithera Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Calithera Biosciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Calithera Biosciences

Our stock analysis for Calithera Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Calithera Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.